化学療法治療の世界市場2019-2023

Technavioが発行した調査報告書(IRTNTR31249)
◆英語タイトル:Global Chemotherapy Treatment Market 2019-2023
◆商品コード:IRTNTR31249
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年5月16日
◆ページ数:136
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、化学療法治療の世界市場について調査・分析し、市場概要、市場環境、化学療法治療市場規模、薬の種類別(抗代謝剤、植物誘導体、細胞傷害性抗生物質、アルキル化剤、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・化学療法治療の世界市場概要
・化学療法治療の世界市場環境
・化学療法治療の世界市場動向
・化学療法治療の世界市場規模
・化学療法治療の世界市場:業界構造分析
・化学療法治療の世界市場:薬の種類別(抗代謝剤、植物誘導体、細胞傷害性抗生物質、アルキル化剤、その他)
・化学療法治療の世界市場:地域別市場規模・分析
・化学療法治療の北米市場規模・予測
・化学療法治療のヨーロッパ・中東・アフリカ市場規模・予測
・化学療法治療のアジア太平洋市場規模・予測
・化学療法治療の主要国分析
・化学療法治療の世界市場:意思決定フレームワーク
・化学療法治療の世界市場:成長要因、課題
・化学療法治療の世界市場:競争環境
・化学療法治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market

The recent approvals of chemotherapeutics to treat cancer is one of the key factors expected to trigger the chemotherapy treatment market during the forecast period. With the rising prevalence of cancer, the demand for chemotherapeutics agents is increasing. The market has witnessed recent approvals of chemotherapeutics agents such as TECENTRIQ by regulatory authorities in different regions. TECENTRIQ in combination with carboplatin and etoposide is being used for first-line treatment of adult patients with extensive-stage, small-cell lung cancer. This will boost the chemotherapy treatment market growth during the forecast period. Technavio’s analysts have predicted that the chemotherapy treatment market will register a CAGR of nearly 3% by 2023.

Market Overview

Availability of drugs to treat the side-effects of chemotherapy

The drugs used in chemotherapy for cancer treatment have several side-effects such as vomiting and nausea, hypersensitivity reactions, and neutropenia. Hence, the availability of drugs to treat these side-effects will drive the growth of the market during the forecast period.

Emerging targeted therapies

The market has witnessed the development and approval of targeted therapies to treat different cancers, such as prostate cancer, lung and bronchus cancer, and thyroid cancer. This may pose a challenge to the global chemotherapy treatment market.

For the detailed list of factors that will drive and challenge the growth of the chemotherapy treatment market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Several vendors in the market are focusing on the development of combination therapies with chemotherapy drugs along with targeted therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY DRUG CLASS

Market segmentation by drug class

Comparison by drug class

Antimetabolites – Market size and forecast 2018-2023

Plant derivatives – Market size and forecast 2018-2023

Cytotoxic antibiotics – Market size and forecast 2018-2023

Alkylating agents – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by drug class

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Market trends

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb Co.

Eli Lilly and Co.

Johnson & Johnson Services Inc.

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Combination therapy approvals

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Drug class – Market share 2018-2023 (%)

Exhibit 19: Comparison by drug class

Exhibit 20: Antimetabolites – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Antimetabolites – Year-over-year growth 2019-2023 (%)

Exhibit 22: Plant derivatives – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Plant derivatives – Year-over-year growth 2019-2023 (%)

Exhibit 24: Cytotoxic antibiotics – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Cytotoxic antibiotics – Year-over-year growth 2019-2023 (%)

Exhibit 26: Alkylating agents – Market size and forecast 2018-2023 ($ millions)

Exhibit 27: Alkylating agents – Year-over-year growth 2019-2023 (%)

Exhibit 28: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: Others – Year-over-year growth 2019-2023 (%)

Exhibit 30: Market opportunity by drug class

Exhibit 31: Customer landscape

Exhibit 32: Market share by geography 2018-2023 (%)

Exhibit 33: Geographic comparison

Exhibit 34: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: North America – Year-over-year growth 2019-2023 (%)

Exhibit 36: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Approvals of chemotherapeutics

Exhibit 45: Side-effects of chemotherapy drugs

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Combination therapies under late-stage clinical trials

Exhibit 48: Repurposed chemotherapy agents

Exhibit 49: Antibody drug conjugates undergoing clinical trials

Exhibit 50: Vendor landscape

Exhibit 51: Landscape disruption

Exhibit 52: Vendors covered

Exhibit 53: Vendor classification

Exhibit 54: Market positioning of vendors

Exhibit 55: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 56: Bristol-Myers Squibb Co. – Business segments

Exhibit 57: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 58: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 59: Bristol-Myers Squibb Co. – Key offerings

Exhibit 60: Eli Lilly and Co. – Vendor overview

Exhibit 61: Eli Lilly and Co. – Business segments

Exhibit 62: Eli Lilly and Co. – Organizational developments

Exhibit 63: Eli Lilly and Co. – Geographic focus

Exhibit 64: Eli Lilly and Co. – Segment focus

Exhibit 65: Eli Lilly and Co. – Key offerings

Exhibit 66: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 67: Johnson & Johnson Services Inc. – Business segments

Exhibit 68: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 69: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 70: Johnson & Johnson Services Inc. – Segment focus

Exhibit 71: Johnson & Johnson Services Inc. – Key offerings

Exhibit 72: Novartis AG – Vendor overview

Exhibit 73: Novartis AG – Business segments

Exhibit 74: Novartis AG – Organizational developments

Exhibit 75: Novartis AG – Geographic focus

Exhibit 76: Novartis AG – Segment focus

Exhibit 77: Novartis AG – Key offerings

Exhibit 78: Pfizer Inc. – Vendor overview

Exhibit 79: Pfizer Inc. – Business segments

Exhibit 80: Pfizer Inc. – Organizational developments

Exhibit 81: Pfizer Inc. – Geographic focus

Exhibit 82: Pfizer Inc. – Segment focus

Exhibit 83: Pfizer Inc. – Key offerings

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Definition of market positioning of vendors



【掲載企業】

Bristol-Myers Squibb Co.、Eli Lilly and Co.、Johnson & Johnson Services Inc.、Novartis AG、Pfizer Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 化学療法治療の世界市場2019-2023(Global Chemotherapy Treatment Market 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆